iSpecimen Receives Nasdaq Delisting Notice for Equity Deficiency

summarizeSummary

iSpecimen Inc. received a formal notice from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement, putting its listing at risk.

check_boxKey Events

• Nasdaq Delisting Notice Received

  On May 29, 2026, iSpecimen Inc. received a formal notice from Nasdaq for non-compliance with Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity.

• Significant Equity Deficiency

  The company reported stockholders' equity of $814,038 as of March 31, 2026, which is substantially below the required $2.5 million minimum. Nasdaq also noted non-compliance with alternative listing standards.

• Compliance Plan Required

  iSpecimen has 45 calendar days from the notice date to submit a plan to regain compliance. If accepted, an extension of up to 180 calendar days may be granted.

• No Immediate Trading Halt

  The notice has no immediate effect on the listing or trading of the company's common stock, which continues to trade on the Nasdaq Capital Market.

auto_awesomeAnalysis

iSpecimen Inc. received a formal notice from Nasdaq for failing to meet the minimum stockholders' equity requirement. This is a critical development for a company already facing severe financial challenges, including a going concern warning and drastic revenue declines reported in its recent 10-K and 10-Q filings. Despite a recent $2.5 million private placement, the company's equity remains significantly below Nasdaq's threshold, indicating deep-seated financial distress. While there is a 45-day period to submit a compliance plan, the risk of delisting is substantial and would severely impact the company's ability to raise capital and maintain investor confidence.